2014
DOI: 10.1016/s0924-977x(14)70743-6
|View full text |Cite
|
Sign up to set email alerts
|

P.2.f.022 Vortioxetine versus escitalopram in adults with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2014
2014
2015
2015

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 1 publication
0
5
0
Order By: Relevance
“…The difference in nausea rates is likely because individuals already exposed to vortioxetine in the lead-in study (as opposed to those who switched treatments in the OLE) were acclimated to the treatment. Two recently published clinical trials in which MDD patients previously treated with SSRIs were directly switched to vortioxetine reported that the incidence of nausea associated with switching to vortioxetine was less in patients who had been previously treated with an SSRI ( Montgomery et al , 2014 ; Jacobsen et al , 2015b ).…”
Section: Discussionmentioning
confidence: 99%
“…The difference in nausea rates is likely because individuals already exposed to vortioxetine in the lead-in study (as opposed to those who switched treatments in the OLE) were acclimated to the treatment. Two recently published clinical trials in which MDD patients previously treated with SSRIs were directly switched to vortioxetine reported that the incidence of nausea associated with switching to vortioxetine was less in patients who had been previously treated with an SSRI ( Montgomery et al , 2014 ; Jacobsen et al , 2015b ).…”
Section: Discussionmentioning
confidence: 99%
“…In an 8-week, randomized, double-blind trial, 447 patients with well-controlled MDD and treatment-emergent sexual dysfunction on SSRI therapy were randomized to switch to either vortioxetine or escitalopram (each starting at 10 mg daily with potential dose increases to 20 mg) [41]. The primary endpoint was a change from baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) total score at week 8.…”
Section: Sexual Dysfunctionmentioning
confidence: 99%
“…A previous meta-analysis of treatmentemergent sexual dysfunction (as measured by various methods) in antidepressants found that SSRIs and SNRIs had rates of sexual dysfunction ranging from 25 to 80%, with fluoxetine, paroxetine, citalopram, venlafaxine and sertraline all having rates greater than 70% [50]. Further, in a trial of patients with treatment-emergent sexual dysfunction on SSRI treatment, those who were switched to vortioxetine showed significant improvement in CSFQ-14 total score as compared to patients who were switched to escitalopram [41]. Based on available data, vortioxetine appears advantageous in that it may have a lower incidence of sexual dysfunction than SSRIs or SNRIs and may potentially even reverse SSRIinduced sexual dysfunction.…”
Section: Vortioxetinementioning
confidence: 99%
“…However, relative to escitalopram 10-20 mg/day, vortioxetine 10-20 mg/day was associated with a significantly (p = 0.013) greater improvement in sexual dysfunction measures in a study in patients with well-controlled MDD who were experiencing treatment-emergent sexual dysfunction during prior treatment with SSRIs [37].…”
Section: Sexual Dysfunctionmentioning
confidence: 90%